Hematological Malignancy Clinical Trial
Official title:
A Multicenter Randomized Controlled Study of Shengxuening Tablet in the Treatment of Chemotherapy-related Anemia in Hematologic Tumors
Cancer-related anemia (CRA) is one of the common accompanying diseases of malignant tumors. In 2019, a cross-sectional survey on the anemia status of 7324 malignant tumor patients in 97 hospitals in China found that the incidence of CRA was about 49.24%. 92.84% of the patients have not been given enough attention and effective treatment. According to the European Oncological Anemia Survey, CRA has the highest incidence in leukemia patients, followed by lymphoma/myeloma. CRA not only leads to a decline in the quality of life of patients, but also reduces the sensitivity to radiotherapy and chemotherapy, and also causes hypoxia in tumor tissue, which affects the prognosis of patients as an independent factor. At present, the treatment of CRA mainly includes blood transfusion therapy, erythropoiesis-stimulating agent (ESA) therapy, iron supplementation, etc. Conventional oral iron has low bioavailability and strong gastrointestinal irritation. Although intravenous iron can quickly replenish iron, excessive iron supplementation is prone to iron overload. Less acceptable. Shengxuening Tablets are derived from silkworm excrement. The main components of iron chlorophyllin and chlorophyll derivatives are very similar in structure to heme, and can be directly absorbed by small intestinal mucosal cells, effectively supplementing the iron elements required in the process of hematopoiesis. The investigators found that Shengxuening Tablets can increase the number of peripheral blood cells in mouse models of myelosuppression, improve bone marrow morphology, reverse the decrease in body weight and spleen index, and increase the levels of serum erythropoietin and granulocyte-macrophage colony-stimulating factor . Real-time fluorescent quantitative PCR and Western blot analysis showed increased expression levels of stem cell factor (SCF), JAK2 and STAT3 in the liver. These results indicated that Shengxuening Tablets promoted the recovery of hematopoietic function in myelosuppressive models by increasing the secretion of hematopoietic factors and activating the JAK2/STAT3 pathway. Therefore, in order to further confirm the preventive effect, effectiveness and safety of Shengxuening Tablets in the treatment of anemia in patients with hematological tumors complicated with anemia, this clinical trial was designed.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04932967 -
Use of nMoABs for the Treatment of COVID-19 in Patients With HM.
|
||
| Not yet recruiting |
NCT02900768 -
Effects of Exercise on Allogeneic Stem Cell Transplant
|
N/A | |
| Recruiting |
NCT04082910 -
Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05510089 -
Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies
|
N/A | |
| Terminated |
NCT04093622 -
Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
|
||
| Recruiting |
NCT06225856 -
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies
|
Phase 1 | |
| Recruiting |
NCT06106360 -
A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
|
||
| Recruiting |
NCT02828462 -
Impact of a Monitoring Device for Patients With Cancer Treated Using Oral Therapeutics
|
||
| Completed |
NCT01714180 -
Effect of Body Mass on Acyclovir Pharmacokinetics
|
N/A | |
| Completed |
NCT03241550 -
A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
|
Phase 1 | |
| Active, not recruiting |
NCT04684108 -
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
|
Phase 1 | |
| Completed |
NCT02598752 -
Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation
|
||
| Completed |
NCT02880709 -
The Effect of Special Diets in Hematological Cancer Patients
|
Phase 4 | |
| Completed |
NCT00894049 -
A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation
|
Phase 2 | |
| Completed |
NCT04687982 -
Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentical Transplantation With Post-transplantation Cyclophosphamide in Patients With Hematological Malignancies (ONC-2016-002).
|
N/A | |
| Completed |
NCT00897260 -
Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders
|
N/A | |
| Recruiting |
NCT03850366 -
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
|
Phase 2 | |
| Not yet recruiting |
NCT06066255 -
PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM
|
Phase 2 | |
| Enrolling by invitation |
NCT05364359 -
Individual Dietary Counseling Based on Taste-tests in Patients With Hematological Cancer in Cytostatic Therapy
|
N/A | |
| Recruiting |
NCT04841447 -
Membrane Target Detection for Leukemia Treatment
|